Supply Chain Issues Leading To Price Hikes

 

Key Points:

  • A lot of issues in the supply chain can be attributed to an increase in demand that can’t be met, leading to longer wait times and price hikes.
  • The supply chain is struggling to adapt to higher labor costs, slowing down production.
  • Workers long term should be able to adjust over time as the job market changes to deal with supply chain issues. Producers will need to learn how to adjust to various changes in the next couple years, and consumers short term need to adjust to longer wait times for orders.

Commentary:

Supply chain issues…at this point, it’s a challenge both producers and consumers are very familiar with. There’s a general lack of products, yes. Consumers, though, are especially weary of price hikes like the ones announced by Procter & Gamble, which announced it would be raising prices on certain products from haircare to tooth paste; when a major player in the industry makes a decision like that, it’s definitely concerning and telling of more inflationary prices to come. MarketScale wanted to know: Is this recent price hike a sign of things to come for other major producers? Arjun Chandler, founder and CEO of IndustriaML, gives his thoughts on what is causing these problems and what the future could hold both in the short term and the long term.

Abridged Thoughts:

A lot of the manufacturing jobs that existed before the pandemic, they’re struggling to hire new people. And because of that labor shortage, which is somewhat of a global problem, especially prevalent in the United States, it is difficult for manufacturers to produce at the same rate. It’s not an issue of lack of raw material availability. Ultimately, where people get their precious metals from, et cetera, that’s still, there has not really been an issue on the supply side there. It’s been the ability to assemble and ship pieces that has really suffered because of a labor shortage.

More Stories Like This:

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Have People Stopped Making Travel Decisions Based on Price?

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More